Top

Clinical Reviews in Allergy & Immunology

Published in:

01-10-2008

Antineutrophil Cytoplasmic Autoantibodies: How Should the Biologist Manage Them?

Authors: C. Beauvillain, Y. Delneste, G. Renier, P. Jeannin, J. F. Subra, A. Chevailler

Published in: Clinical Reviews in Allergy & Immunology | Issue 1-2/2008

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) are directed against enzymes found in the granules of the polymorphonuclear (PMN) leukocytes. They are detected by indirect immunofluorescence microscopy assays on human ethanol fixed neutrophils. Three different fluorescence patterns can be distinguished: a cytoplasmic pattern (cANCA), a perinuclear pattern (pANCA), and an atypical pattern (aANCA). The use of other fixatives, e.g., formalin and methanol, allows differentiation between the pANCA and the antinuclear antibodies. ANCA specificity is determined by solid phase assays (ELISA, immunodot, and multiplex assay). ANCA with high titres and defined specificities (antiproteinase 3 [PR 3] or antimyeloperoxidase [MPO]) are proven to be good serological markers of active primary systemic vasculitis: c/PR 3-ANCA for Wegener’s granulomatosis and p/MPO-ANCA for microscopic polyangiitis. The former have higher sensitivity and specificity for Wegener’s granulomatosis than the latter for microscopic polyangiitis. ANCA with low titres and unknown specificity have been detected in a wide range of inflammatory and infectious diseases leading to a critical reappraisal of the diagnostic significance of ANCA testing. Physicians must keep in mind the possible occurrence of infectious diseases like subacute endocarditis that could be dramatically worsened by irrelevant immunosuppressive therapy. ANCA findings in certain manifestations, such as the pulmonary-renal syndrome in which massive pulmonary hemorrhage can quickly be life-threatening, warrant ANCA testing as an emergency test for patient care.

van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem GK, The TH (1985) Antibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1:425–429PubMed

Mohan N, Kerr GS (2001) Best Pract Res Clin Rheumatol 15:203–223PubMedCrossRef

Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRef

Davies DJ, Moran JE, Niall JF, Ryan GB (1982) Segmental necrotizing glomerulonephritis with anti-neutrophil antibody: possible arbovirus aetiology? Br Med J 285:606

Savige J, Pollock W, Trevisin M (2005) What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol 19:263–276PubMedCrossRef

Bajema IM, Hagen EC, Ferrario F, de Heer E, Bruijn JA (2001) Immunopathological aspects of systemic vasculitis. Springer Semin Immunopathol 23:253–265PubMedCrossRef

Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L (2000) Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 80:617–653PubMed

Falk RJ, Terrell RS, Charles LA, Jennette JC (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115–4119PubMedCrossRef

Ralston DR, Marsh CB, Lowe MP, Wewers MD (1997) Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest 100:1416–1424PubMedCrossRef

10.

Lee AS, Finkielman JD, Peikert T, Hummel AM, Viss MA, Jacob GL, Homburger HA, Specks U, Wegener’s Granulomatosis Etanercept Trial Research Group (2006) Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma. Clin Exp Immunol 146:15–20PubMedCrossRef

11.

Wiik A (1989) Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. Acta Pathol Microbiol Scand 97:12–13

12.

Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318:1651–1657PubMedCrossRef

13.

Wiik A, Rasmussen N, Wieslander J (1994) Methods to detect autoantibodies to neutrophilic granulocytes. In: van Venrooij WJ, Maini RN (eds) Manual of biological markers of diseases. Kluwer Academic Publishers, Dordrecht A9, pp 1–14

14.

Wieslander J, Wiik A (1994) ANCA antigens: myeloperoxydase. In: van Venrooij WJ, Maini RN (eds) Manual of biological markers of diseases. Kluwer Academic Publishers, Dordrecht B7.2, pp 1–9

15.

Savige JA, Paspaliaris B, Silvestrini R, Davies D, Nikoloutsopoulos T, Sturgess A, Neil J, Pollock W, Dunster K, Hendle M (1998) A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J Clin Pathol 51:568–575PubMed

16.

Chevailler A, Noel LH, Renier G, Gardembas-Pain M, Subra JF, Nusbaum P, Hurez D, Lesavre P (1992) Unambiguous determination of anti-neutrophil cytoplasm antibodies (ANCA) specificity by immunofluorescence on chronic myelocytic leukemia cells. J Immunol Methods 147:101–109PubMed

17.

Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, Hagen EC, Jayne D, Jennette JC, Paspaliaris B, Pollock W, Pusey C, Savage CO, Silvestrini R, van der Woude F, Wieslander J, Wiik A (1999) International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 111:507–513PubMed

18.

Wiik A (2001) Anti-neutrophil cytoplasmic antibodies tests: which tests should be used in practice? Internal Med 40:446–470CrossRef

19.

Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR (1988) A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamster. J Clin Invest 82:1963–1973PubMedCrossRef

20.

Goldschmeding R, van der Schoot CE, ten Bokkell Huinink D, Hack CE, van den Ende ME, Kallenberg CGM, von dem Borne AE (1989) Wegener’s granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 84:1577–1587PubMedCrossRef

21.

van der Geld YM, Limburg PC, Kallenberg CGM (2001) Proteinase 3, Wegener’s autoantigen: from gene to antigen. J Leukoc Biol 69:177–190PubMed

22.

Wiik A (2001) Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommandation for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results. Springer Semin Immunopathol 23:217–229PubMedCrossRef

23.

Wieslander J, Wiik A (1994) ANCA antigens: proteinase 3. In: van Venrooij WJ, Maini RN (eds) Manual of biological markers of diseases. Kluwer Academic Publishers, Dordrecht B7.1, pp 1–9

24.

Gross WL, Csernok E, Szymkowiak CH (1996) Antineutrophil cytoplasmic autoantibodies with specificity for proteinase 3. In: Peter JB, Shoenfeld Y (eds) Autoantibodies. Elsevier, Amsterdam, pp 61–67CrossRef

25.

Sun J, Fass DN, Viss MA, Hummel AM, Tang H, Homburger HA, Specks U (1998) A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol 114:320–326PubMedCrossRef

26.

Taekema-Roelvink MEJ, van Kooten C, Verburgh CA, Daha MR (2001) Role of proteinase 3 in activation of endothelium. Springer Semin Immunopathol 23:299–314PubMedCrossRef

27.

Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V (1995) Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Lett 374:29–33PubMedCrossRef

28.

Witko-Sarsat V, Lesavre P, Lopez S, Bessou G, Hieblot C, Prum B, Noël LH, Guillevin L, Ravaud P, Sermet-Gaudelus I, Timsit J, Grünfeld JP, Halbwachs-Mecarelli L (1999) A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 10:1224–1233PubMed

29.

Esnault VL, Testa A, Audrain M, Roge C, Hamidou M, Barrier JH, Sesboüé R, Martin JP, Lesavre P (1993) Alpha1-anti-trypsin genetic polymorphism in ANCA positive systemic vasculitis. Kidney Int 43:1323–1332CrossRef

30.

Audrain MA, Sesboue R, Baranger TAR, Elliott J, Testa A, Martin JP, Lockwood CM, Esnault VL (2001) Analysis of anti-neutrophil antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha-1-antitrypsin-deficient subjects. Nephrol Dial Transplant 16:39–44PubMedCrossRef

31.

Wieslander J, Wiik A (1994) ANCA antigens: myeloperoxidase. In: van Venrooij WJ, Maini RN (eds) Manual of biological markers of diseases. Kluwer Academic Publishers, Dordrecht B7.2, pp 1–9

32.

Kallenberg CGM (1996) Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase. In: Peter JB, Shoenfeld Y (eds) Autoantibodies. Elsevier, Amsterdam, pp 53–60CrossRef

33.

Kallenberg CGM (2007) Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase. In: Shoenfeld Y, Gershwin ME, Meroni PL (eds) Autoantibodies. Elsevier, Amsterdam, pp 95–103CrossRef

34.

Boomsma MM, Stegeman CA, Oost-Kort WW, Kallenberg CGM, Moguilevsky N, Limburg PC, Tervaert JW (2001) Native and recombinant proteins to analyze autoantibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis. J Immunol Methods 254:47–58PubMedCrossRef

35.

Falk RJ, Becker M, Terrell R, Jennette JC (1992) Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase. Clin Exp Immunol 89:274–278PubMedCrossRef

36.

Segelmark M, Baslund B, Wieslander J (1994) Some patients with antimyeloperoxidase autoantibodies have a cANCA pattern. Clin Exp Immunol 96:458–465PubMedCrossRef

37.

Chevailler A, Subra JF, Renier G, Carrère F, Hurez D (1993) Anti-myeloperoxidase antibodies and associated diseases. In: Gross WL (ed) ANCA- associated vasculitides: immunological and clinical aspects. Plenum Press, New York, pp 263–266

38.

Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Lüdemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ (1998) The diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies (ANCA) in idiopathic systemic vasculitis. Results of an international collaborative study. Kidney Int 53:743–753PubMedCrossRef

39.

Zhao MH, Lockwood CM (1996) Antineutrophil cytoplasmic autoantibodies with specificity other than PR3 and MPO (x-ANCA). In: Peter JB, Shoenfeld Y (eds) Autoantibodies. Elsevier, Amsterdam, pp 68–73CrossRef

40.

Zhao MH, Jones SJ, Lockwood CM (1995) Bactericidal/permeability increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 99:49–56PubMedCrossRef

41.

Schultz H, Weiss J, Carroll SF, Gross WL (2001) The endotoxin bactericidal/permeability increasing protein (BPI): a target of autoantibodies. J Leukoc Biol 69:505–512PubMed

42.

Segelmark M, Westman K, Wieslander J (2000) How and why should we detect ANCA? Clin Exp Rheumatol 18:629–635PubMed

43.

Zhao MH, Lockwood CM (1996) Azurocidin is a novel antigen for anti-neutrophil cytoplasmic antibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 103:397–402PubMedCrossRef

44.

Nassberger L, Jonsson H, Sjoholm AG, Sturfelt G, Heubner A (1989) Circulating antielastase in systemic lupus erythematosus. Lancet 1:509PubMedCrossRef

45.

Halbwachs-Mecarelli L, Nusbaum P, Noel LH, Reumaux D, Erlinger S, Grünfeld JP, Lesavre P (1992) Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn’s disease and primary sclerosing cholangitis. Clin Exp Immunol 90:79–84PubMedCrossRef

46.

Corremans IE, Hagen EC, Daha MR, van der Voort EA, Kleijburg-van der Keur C, Breedveld FC (1992) Antilactoferrin antibodies in patients with arthritis are associated with vasculitis. Arthritis Rheum 35:1466–1475CrossRef

47.

Gallin MY, Jacobi AB, Buttner DW, Schoenberger O, Marti T, Ertman KDA (1995) Human autoantibody to defensin: disease association with hyperactive onchocerciasis. J Exp Med 182:41–47PubMedCrossRef

48.

Schmitt WH, Csernok E, Flesch BK, Hauschild S, Gross WL (1993) Autoantibodies directed against lysozyme: a new target antigen for antineutrophil cytoplasmic antibodies (ANCA). In: Gross WL (ed) ANCA- associated vasculitides: immunological and clinical aspects. Plenum Press, New York, pp 267–272

49.

Nassberger L, Ljungh A, Schumacher G, Kollberg B (1992) β-glucuronidase in ulcerative colitis. Lancet 340:734–735PubMedCrossRef

50.

Moodie FD, Leaker B, Cambridge G, Totty NF, Segal AW (1993) Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis. Kidney Int 43:675–681PubMedCrossRef

51.

Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, Kerjaschki D (1995) A novel class of autoantigens of antineutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granules and a related membrane proteine in glomerular endothelial cells. J Exp Med 181:585–597PubMedCrossRef

52.

Talor MV, Stone JH, Stebbing J, Barin J, Rose NR, Burek CL (2007) Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 150:42–48PubMedCrossRef

53.

54.

van der Woude FJ, Daha MR, van Es LA (1989) The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol 78:143–148PubMed

55.

Hagen EC, Andrassy K, Chernok E, Daha MR, Gaskin G, Gross W, Lesavre P, Lüdemann J, Pusey CD, Rasmussen N et al (1993) The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 159:1–16PubMedCrossRef

56.

Hagen EC, Andrassy K, Csernok E, Daha MR, Gaskin G, Gross W, Hansen B, Heigl Z, Hermans J, Jayne D, Kallenberg CG, Lesavre P, Lockwood CM, Lüdemann J, Mascart-Lemone F, Mirapeix E, Pusey CD, Rasmussen N, Sinico RA, Tzioufas A, Wieslander J, Wiik A, Van der Woude FJ (1996) Development of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the stardardization of ANCA assays. J Immunol Methods 196:1–15PubMedCrossRef

57.

Audrain MA, Reumaux D, Gerson F, Duthilleul P, Wiik A, Muller JY, Esnault VL (1999) Contamination of commercially purified myeloperoxidase preparations by lactoferrin. J Immunol Methods 222:219–220PubMedCrossRef

58.

Jethwa HS, Nachman PH, Falk RJ, Jennette JC (2000) False-positive myeloperoxidase binding activity due to DNA/anti-DNA antibody complexes: a source for analytical error in serologic evaluation of anti-neutrophil cytoplasmic antibodies. Clin Exp Immunol 121:544–550PubMedCrossRef

59.

Westman KW, Selga D, Bygren P, Segelmark M, Baslund B, Wiik A, Wieslander J (1998) Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. Kidney Int 53:1230–1236PubMedCrossRef

60.

Damoiseaux J, Vaessen M, Knapen Y, Csernok E, Stegeman CA, Van Paassen P, Cohen Tervaert JW (2007) Evaluation of the FIDIS vasculitis multiplex immunoassay for diagnosis and follow-up of ANCA-associated vasculitis and Goodpasture’s disease. Ann N Y Acad Sci 1109:454–463PubMedCrossRef

61.

Lim L, Taylor J, Schmitz J, Folds J, Wilkman A, Falk RJ, Jennette JC (1999) Diagnostic usefulness of antineutrophil cytoplasmic antibody serology. Am J Clin Path 111:363–369PubMed

62.

Subra JF, Michelet C, Laporte J, Carrere F, Reboul P, Cartier F, Saint-André JP, Chevailler A (1998) The presence of cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) in the course of subacute bacterial endocarditis with glomerular involvement, coincedence or association? Clin Nephrol 49:15–18PubMed

63.

Soto A, Jorgensen C, Oksman F, Noel LH, Sany J (1994) Endocarditis associated with ANCA. Clin Exp Rheumatol 12:203–204PubMed

64.

Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, Peikert T, Hoffman GS, Merkel PA, Spiera R, St Clair EW, Davis JC Jr, McCune WJ, Tibbs AK, Ytterberg SR, Stone JH, Specks U, WGET Research Group (2007) ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med 120:643PubMedCrossRef

65.

Choi HK, Merkel PA, Walker AM, Niles JL (2000) Drug-associated antineutrophil cytoplasmic antibodies-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43:405–413PubMedCrossRef

66.

De’Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD (1995) Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 25:380–389PubMedCrossRef

67.

Cohen-Tervaert JW, Huitema MG, Hene RJ, Sluiter WJ, The TH, van der Hem GK, Kallenberg CG (1990) Prevention of relapses in Wegener’s granulomatosis by treatment based on anti-neutrophil cytoplasmic antibodies titre. Lancet 336:709–711CrossRef

68.

Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS (1993) Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 36:365–371PubMedCrossRef

69.

Mukhtyar C, Flossmann O, Hellmich B, Bacon PA, Cid MC, Cohen Tervaert JW, Gross WL, Guillevin L, Jayne DR, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA (2007) Outcomes from studies of Antineutrophil Cytoplasm Antibody Associated Vasculitis: a systematic review by the EULAR Systemic Vasculitis Task Force. Ann Rheum Dis Oct 2; [Epub ahead of print]

70.

Sinclair D, Saas M, Stevens JM (2004) The effect of a symptom related “gating policy” on ANCA requests in routine clinical practice. J Clin Pathol 57:131–134PubMedCrossRef

71.

Stegeman CA, Kallenberg CGM (2001) Clinical aspects of primary vasculitis. Springer Semin Immunopathol 23:231–251PubMedCrossRef

72.

Radice A, Sabadini E, Sinico RA (2007) Antineutrophil cytoplasmic autoantibodies with specificity for proteinase 3. In: Shoenfeld Y, Gershwin ME, Meroni PL (eds) Autoantibodies. Elsevier, Amsterdam, pp 105–110CrossRef

73.

Aries P, Csernok E, Gross L (2007) Antineutrophil cytoplasmic autoantibodies with specificity for proteinase 3. In: Shoenfeld Y, Gershwin ME, Meroni PL (eds) Autoantibodies. Elsevier, Amsterdam, pp 119–126CrossRef

74.

Pendergraft WF 3rd, Preston GA, Shah RR, Tropsha A, Carter CW Jr, Jennette JC, Falk RJ (2004) Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10:72–79PubMedCrossRef

75.

Chevailler A, Carrère F, Renier G, Hurez D, Subra JF, Reboul P, Riberi P, Masson C (1994) Silicon nephropathy and myeloperoxydase antibodies. Ann Rheum Dis 53:781–782PubMedCrossRef

76.

Gregorini G, Tira P, Frizza J, D’Haese PC, Elseviers MM, Nuyts G, Maiorca R, De Broe ME (1997) ANCA-associated diseases and silica exposure. Clin Rev Allergy Immunol 15:21–40PubMedCrossRef

77.

Hogan SL, Cooper GS, Savitz DA, Nylander-French LA, Parks CG, Chin H, Jennette CE, Lionaki S, Jennette JC, Falk RJ (2007) Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol 2:290–299PubMedCrossRef

78.

Griffith ME, Pusey CD (2001) Cellular aspects of vasculitis– T cell-mediated aspects. Springer Semin Immunopathol 23:287–298PubMedCrossRef

79.

Subra JF, Renier G, Reboul P, Tollis F, Boivinet R, Schwartz P, Chevailler A (2001) Lymphopenia in occupational pulmonary silicosis with or without autoimmune disease. Clin Exp Immunol 126:540–544PubMedCrossRef

Title: Antineutrophil Cytoplasmic Autoantibodies: How Should the Biologist Manage Them?
Authors: C. Beauvillain
Y. Delneste
G. Renier
P. Jeannin
J. F. Subra
A. Chevailler
Publication date: 01-10-2008
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 1-2/2008
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-007-8071-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2008

The Geo-epidemiology of Temporal (Giant Cell) Arteritis

Advances in the Treatments of Systemic Vasculitides

Vasculitis: Current Status and Future Directions

Animal Models of Vasculitides

Renal Involvement in Wegener’s Granulomatosis

The Last Classification of Vasculitis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials